Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir triple therapy versus pegylated interferon/ribavirin for acute hepatitis C genotype 1 in HIV-1 coinfected patients
2012-001419-21Phase 4Completed
- Sponsor
- Universitätsklinikum Bonn
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of telaprevir, pegylated interferon alpha and ribavirin in hepatitis C virus infection and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Universitätsklinikum Bonn. Primary endpoint: Sustained virological response at 24 weeks after end of treatment. Started Apr 2013; status: completed.
02
Drugs
telaprevirpegylated interferon alpharibavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2012-001419-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001419-21.